Rigel(RIGL) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., August 5, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the second quarter ended June 30, 2025, including sales of TAVALISSE (fostamatinib disodium hexahydrate), GAVRETO (pralsetinib) and REZLIDHIA (olutasidenib), and recent business progress. "Ou ...